This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Abbott cannot amend claims in Dexcom patent case, UPC’s Paris division says

( October 11, 2024, 14:39 GMT | Official Statement) -- MLex Summary: Abbott’s bid to amend its claims in the Dexcom patent infringement case concerning glucose monitoring technology was today rejected by the Unified Patent Court's Paris Local Division. The court ruled that Abbott’s proposed amendments — linked to an app update for its LibreLinkUp app disclosed in late September — would unfairly delay the proceedings ahead of the Oct. 30 oral hearing. Court document attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections